Devastating infectious diseases cause suffering and death for millions of people around the globe. For many years, most of the investment in addressing these global health challenges was focused on basic disease research, while nearly all product development efforts were focused on larger markets in the developed world.

At IDRI, we are the bridge between knowledge and action. We combine our passion for improving human health with the understanding that it is not just what we know about disease, but what we do to change its course that will have the greatest impact. Developing products that solve intractable global health challenges is what we do, and we have a track record of doing it successfully. Our unique product-based approach to fighting infectious diseases has already yielded novel diagnostics, vaccines and drug development strategies that are protecting and saving lives.


With deep relationships in the academic and corporate arenas, IDRI unites the best of the research and product development communities. Our partnerships with businesses, nonprofits, foundations and government agencies give us unprecedented access to cutting-edge technology and financial support.

We believe our comprehensive approach – combining the high-quality science of a research organization with the product development capabilities of a biotech company – will help us reach our goal of creating new diagnostics, drugs and vaccines to help those who need it most.

  • 501(c)3 nonprofit institution founded by Steven G. Reed, Ph.D., in 1993
  • Headquartered in Seattle with 100+ collaborations worldwide
  • 125+ employees, of which ~50 have advanced degrees (Ph.D) and ~90 work in research and development
  • $22.5 million budget in 2016
  • Bill & Melinda Gates Foundation
  • National Institutes of Health
  • Eli Lilly & Co.
  • Paul G. Allen Family Foundation
  • Wellcome Trust
  • M.J. Murdock Charitable Trust
  • GlaxoSmithKline
  • American Leprosy Missions
  • World Health Organization
  • Other public/private partnerships



We apply innovative science to develop products to eliminate infectious diseases of global importance.


We envision a world in which infectious diseases are either prevented or rapidly diagnosed and treated using products that are available to all people.


  • Compassion: We are driven by compassion and the belief that all people should be free from infectious diseases. Our work holds the promise of saving millions of lives and improving quality of life.
  • Scientific Excellence: We are rooted in scientific excellence, respect for our colleagues and commitment to the creativity, integrity and discipline required to conduct our work.
  • Impact: We believe our research and development, through teamwork and innovation, will have significant impact to improve health locally and globally.


As an undergraduate, Steve Reed had an advisor who worked on infectious diseases in Central America. Later, in the 1990s during travels to Brazil, Steve saw children being physically restrained as they were tested for leishmaniasis, a devastating infectious disease, which could only be detected through painful, invasive biopsies. These experiences raised Steve’s awareness of the tremendous global health challenges posed by infectious diseases, and the equally substantial opportunities to make a difference in millions of lives by developing solutions to these challenges.

Based on his experiences, Steve established IDRI in 1993 to apply advances in immunology to the development of novel diagnostics, vaccines and drugs that could transform the lives of the millions of people at risk for infectious diseases throughout the developing world.


As a scientist with experience in both the academic and biotechnology arenas, Steve had a unique perspective. His goal: to build an institution that combined the high quality science of a research organization with the product development and production capabilities of a biotechnology company.

Today, IDRI has brought together a dedicated team of scientists from around the world who have keen minds, compassionate hearts and entrepreneurial spirits. Together, we are focused on finding new solutions for leprosy, leishmaniasis and tuberculosis, as well as malaria, HIV/AIDS, Chagas disease, pandemic flu and other infectious diseases of global importance.

As the global health arena evolves, our commitment to improving human health and our pragmatic focus on products should enable us to continue translating science into global health solutions.


In 2013, IDRI moved into a state-of-the-art facility in Seattle’s South Lake Union neighborhood, joining the growing global health/life sciences hub in the area, occupying approximately 55,000 square feet.

The new facility allowed IDRI to consolidate its research, development and translational science programs into a contiguous laboratory space, which in turn promotes both collaboration and communication internally.


Previously, IDRI’s rapidly growing number of staff was spread across three floors of a two-building complex, making conditions for teamwork within the Institute an increasing challenge. IDRI’s current facility has united almost all science onto one floor, creating a more conducive environment for collaboration, training and innovation. The majority of the new space contains general laboratory facilities, as well as specialized spaces such as a GMP manufacturing suite, rooms for drug discovery robotics and IDRI’s new Human Immune Monitoring Center.

The space was also designed with the public in mind, featuring interactive tour stops throughout the lab space that use technology to underscore IDRI’s work in developing vaccines, drugs and diagnostics, as well as large built-in windows to showcase IDRI’s specialized facilities, including manufacturing.